Limitations of the study include the relatively small sample size for long-term follow-up and the potential for bias ... long-term treatment for patients with moderate to severe plaque psoriasis.” ...

If you suffer from psoriasis, cooler weather could be bad news. Learn how high and low humidity levels can affect psoriasis ...

Medically reviewed by Marisa Garshick, MD Psoriasis is a chronic (long-term) inflammatory condition that causes red, itchy patches on the skin. It can appear anywhere on the body, but when it affects ...

Secukinumab delivers sustained efficacy and quality of life improvements in pediatric generalized pustular psoriasis (GPP).

No clinically meaningful differences were observed in the efficacy, safety, pharmacokinetics, and immunogenicity of proposed biosimilar and ustekinumab for the treatment of moderate to severe plaque ...

Psoriasis is more than just a skin condition – it’s an autoimmune disorder that can manifest as scales, spots, or even ...

The company had $583.3 million in cash as of September 30th of 2024; Enough cash to fund its operations until the end of 2027 ...

ESK-001 is under clinical development by Alumis and currently in Phase III for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase III drugs for Plaque Psoriasis (Psoriasis Vulgaris) ...

And if you have psoriasis — an immune-mediated condition that causes scaly patches and raised plaques — painful ... The AAD recommends testing it out on a small area first to see how your ...

SAR-441566 is under clinical development by Sanofi and currently in Phase II for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase II drugs for Plaque Psoriasis (Psoriasis Vulgaris ...